Liquid biopsy is a non-invasive alternative to surgical biopsies that allows clinicians to obtain tumour information from a blood sample and plan treatment appropriately. It can spot changes in tumour gene expression profiles and lay the groundwork for individualised treatment. Early identification, tumour heterogeneity, and drug resistance can all benefit from it. It also detects changes in the epidermal growth factor receptor (EGFR) gene, which are observed in patients with non-small cell lung cancer (NSCLC).
North America dominated the Liquid Biopsy Market in 2027. This can be attributed to rising healthcare costs and increased public awareness of cancer forms and sophisticated diagnostic techniques.
Read More @ https://cmiinfonest.blogspot.com/2022/05/liquid-biopsy-market-global-industry.html
